Investor Presentaiton
Both formulations induced a robust immune response
Serum neutralizing antibody levels
% volunteers
100
80
60
40
40
20
20
0
1
10
1000
10000
100
Neutralizing Titre (1/dil)
RSV low dose at DO
RSV high dose at DO
Placebo at DO
RSV low dose at D84
RSV high dose at D84
Placebo at D84
1. Absence of prior exposure to RSV was determined by measuring serum IgA before vaccination 2. Karron et.al. Am J Respir Crit Care Med Vol 203:5, 2021
35 Vaccines Investor Event
sanofi
Robust neutralizing antibody
response in toddlers not previously
exposed to RSV1
Similar immune response
observed for the Low and High dose
formulations
> Immune response in line with
prior studies that showed
reduction of RSV-medically attended
disease²
Move to phase 3 in H1 2024View entire presentation